Objective:

To address the barriers to the implementation of pharmacogenomic testing in Australia and improve its accessibility.

Approach:

• Recommendations from RCPA: The Royal College of Pathologists of Australasia (RCPA) issued recommendations for expanded public funding, better education for patients and clinicians, and research on genetic variation.

Key Findings:

• Approximately 250,000 hospital admissions in Australia annually result from medication toxicities.
• Pharmacogenomic testing can enhance medication efficacy and reduce adverse drug reactions.
• Access to pharmacogenomic testing is limited, particularly in rural areas, and most tests are not covered under the Medicare Benefits Schedule (MBS).
• The RCPA has submitted applications for public funding for two pharmacogenomic tests, with decisions expected in 2025.

Interpretation:

Limitations:

• Current accessibility to pharmacogenomic testing in Australia is limited.
• Lack of coverage under the MBS restricts availability.

Conclusion:

The RCPA emphasizes the need for improved funding, education, and research to enhance pharmacogenomic testing accessibility in Australia.

Sources:

• Royal College of Pathologists of Australasia